Description: Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase I clinical trial for the treatment of hypothyroidism; and non-aqueous XeriSol and XeriJect technologies for various therapies. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.
Home Page: www.xerispharma.com
180 North LaSalle Street
Chicago,
IL
60601
United States
Phone:
844 445 5704
Officers
| Name | Title |
|---|---|
| Mr. John P. Shannon | CEO & Director |
| Mr. Steven M. Pieper | Chief Financial Officer |
| Ms. Beth P. Hecht J.D. | Chief Legal Officer & Corporate Secretary |
| Mr. Paul R. Edick J.D. | Senior Advisor |
| Dr. Kenneth E. Johnson Pharm. D., Pharm.D. | Senior VP of Global Development & Medical Affairs |
| Ms. Allison Wey | Senior Vice President of Investor Relations & Corporate Communications |
| Mr. Brian Conner | SVP of Quality and Chief Compliance & Risk Officer |
| Ms. Kendal Korte | Senior Vice President of Human Resources |
| Mr. Kevin McCulloch | Chief Commercial Officer |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 3.5255 |
| Price-to-Sales TTM: | 2.8234 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 377 |